Published
2022-11-21
Section
Research Article
How to Cite
MOLNUPIRAVIR: A Promising Antiviral for COVID-19
Ketki Bhave
Third Year B. Pharm Bombay College of Pharmacy
Vaishnavi Adani
Bombay College of Pharmacy
Aditi Ranade
Bombay College of Pharmacy
DOI: https://doi.org/10.36664/bt/2022/v69i1/172477
Keywords: Molnupiravir, Covid 19, Synthesis, Remdesivir.
Abstract
Covid 19 is a pandemic which has affected the whole world. As time passed by mid of February 2020 it was declared as a global pandemic by the WHO. Many people lost their lives due to improper treatment and insufficient knowledge and unavailable hospital treatment about this novel virus. In this article the origin of coronavirus, methods and medicines used in the past to contain it are mentioned. Further this article discusses the newly discovered novel drug molnupiravir, its structure, synthesis, mechanism of action and its effectiveness in treatment of Covid 19. It also mentions the difference between remdesivir and molnupiravir. In synthesis, previous and present approaches are discussed.
Downloads
References
Zhou, P.; Yang, X.-L.; Wang, X.-G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H.-R.; Zhu, Y.; Li, B.; Huang, C.-L.; Chen, H.-D.; Chen, J.; Luo, Y.; Guo, H.; Jiang, R.-D.; Liu, M.-Q.; Chen, Y.; Shen, X.-R.; Wang, X.; Zheng, X.-S.; Zhao, K.; Chen, Q.-J.; Deng, F.; Liu, L.-L.; Yan, B.; Zhan, F.-X.; Wang, Y.-Y.; Xiao, G.-F.; Shi, Z.-L. A Pneumonia Outbreak Associated with a New Coronavirus of Probable Bat Origin. Nature 2020, 579 (7798), 270–273 https://doi.org/10.1038/s41586-020-2012-7.
A new coronavirus associated with human respiratory disease in China | Nature https://www.nature.com/articles/s41586-020-2008-
(accessed 2021 -12 -30). Https://Www.Who.Int/Docs/Default-Source/Coron aviruse/Situation-Reports/20200426-Sitrep-97-Cov id-19.Pd.
Sharma, A.; Tiwari, S.; Deb, M. K.; Marty, J. L. Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): A Global Pandemic and Treatment Strategies. Int. J. Antimicrob. Agents 2020, 56 (2),106054. https://doi.org/10.1016/j.ijantimicag.2020.106054.
(5) Cucinotta, D.; Vanelli, M. WHO Declares COVID-19 a Pandemic. Acta Bio-Medica Atenei Parm. 2020, 91 (1), 157–160. https://doi.org/10.23750/abm.v91i1.9397.
(6) Khuroo, M. S. Chloroquine and Hydroxychloroquine in Coronavirus Disease 2019 (COVID-19). Facts, Fiction and the Hype: A Critical Appraisal. Int.J. Antimicrob. Agents 2020, 56 (3), 106101. https://doi.org/10.1016/j.ijantimicag.2020.106101.
(7) Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies - ScienceDirect https://www.sciencedirect.com/science/article/pii/S 1871402120301375 (accessed 2021 -12 -30).
(8) Musa, A.; Pendi, K.; Hashemi, A.; Warbasse, E.; Kouyoumjian, S.; Yousif, J.; Blodget, E.; Stevens, S.; Aly, B.; Baron, D. A. Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature. West. J. Emerg. Med. 2020, 21 (4), 737–741. https://doi.org/10.5811/westjem.2020.5.47658.
(9) Wang, Y.; Zhang, D.; Du, G.; Du, R.; Zhao, J.; Jin, Y.; Fu, S.; Gao, L.; Cheng, Z.; Lu, Q.; Hu, Y.; Luo, G.; Wang, K.; Lu, Y.; Li, H.; Wang, S.; Ruan, S.; Yang, C.; Mei, C.; Wang, Y.; Ding, D.; Wu, F.; Tang, X.; Ye, X.; Ye, Y.; Liu, B.; Yang, J.; Yin, W.; Wang, A.; Fan, G.; Zhou, F.; Liu, Z.; Gu, X.; Xu, J.; Shang, L.; Zhang, Y.; Cao, L.; Guo, T.; Wan, Y.; Qin, H.; Jiang, Y.; Jaki, T.; Hayden, F. G.; Horby, P. W.; Cao, B.; Wang, C. Remdesivir in Adults with Severe COVID-19: A Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial. The Lancet 2020, 395 (10236), 1569–1578. https://doi.org/10.1016/S0140-6736(20)31022-9.
(10) Remdesivir injection price jumps five times as covid 19 cases rise https://www.businessinsider.in/science/health/news/ remdesivir-injection-price-jumps-five-times-as-cov id-19-cases-rise/articleshow/82083414.cms (accessed 2022 -01 -01).
(11) Silva, N. A. de O.; Zara, A. L. de S. A.; Figueras, A.; Melo, D. O. de. Potential Kidney Damage Associated with the Use of Remdesivir for COVID-19: Analysis of a Pharmacovigilance Database. Cad. Saude Publica 2021, 37 (10), e00077721. https://doi.org/10.1590/0102-311X00077721.
(12) Pettit, N. N.; Pisano, J.; Nguyen, C. T.; Lew, A. K.; Hazra, A.; Sherer, R.; Mullane, K. M. Remdesivir Use in the Setting of Severe Renal Impairment: A Theoretical Concern or Real Risk? Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2021, 73 (11), e3990–e3995. https://doi.org/10.1093/cid/ciaa1851.
(13) Adamsick, M. L.; Gandhi, R. G.; Bidell, M. R.; Elshaboury, R. H.; Bhattacharyya, R. P.; Kim, A. Y.; Nigwekar, S.; Rhee, E. P.; Sise, M. E. Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19. J. Am. Soc. Nephrol. 2020, 31 (7), 1384–1386. https://doi.org/10.1681/ASN.2020050589.
Qureshi, Q. H.; Ashraf, T.; Rehman, K.; Khosa, M. K.; Akash, M. S. H. Therapeutic Interventions of Remdesivir in Diabetic and Nondiabetic COVID-19 Patients: A Prospective Observational Study Conducted on Pakistani Population. J. Med. Virol. 2021, 93 (12), 6732–6736. https://doi.org/10.1002/jmv.27256.
Ackley, T. W.; McManus, D.; Topal, J. E.; Cicali, B.; Shah, S. A Valid Warning or Clinical Lore: An Evaluation of Safety Outcomes of Remdesivir in Patients with Impaired Renal Function from a Multicenter Matched Cohort. Antimicrob. Agents Chemother. 2020. https://doi.org/10.1128/AAC.02290-20.
Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study - Merck.com https://www.merck.com/news/merck-and-ridgeback s-investigational-oral-antiviral-molnupiravir-reduce d-the-risk-of-hospitalization-or-death-by-approxim ately-50-percent-compared-to-placebo-for-patientswith- mild-or-moderat/ (accessed 2022 -01 -01).
Fischer, W.; Eron, J. J.; Holman, W.; Cohen, M. S.; Fang, L.; Szewczyk, L. J.; Sheahan, T. P.; Baric, R.; Mollan, K. R.; Wolfe, C. R.; Duke, E. R.; Azizad, M. M.; Borroto-Esoda, K.; Wohl, D. A.; Loftis, A. J.; Alabanza, P.; Lipansky, F.; Painter, W. P. Molnupiravir, an Oral Antiviral Treatment for COVID-19. medRxiv 2021, 2021.06.17.21258639. https://doi.org/10.1101/2021.06.17.21258639.
How antiviral pill molnupiravir shot ahead in the COVID drug hunt https://www.nature.com/articles/d41586-021-02783 -1 (accessed 2022 -01 -01).
What we know about molnupiravir: Data and safety concerns https://www.medicalnewstoday.com/articles/molnu piravir-vs-covid-19-will-the-drug-live-up-to-the-hy pe (accessed 2022 -01 -01).
Lee, C.-C.; Hsieh, C.-C.; Ko, W.-C. Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent. Antibiotics 2021, 10 (11), 1294. https://doi.org/10.3390/antibiotics10111294.
Hernandez-Santiago, B. I.; Beltran, T.; Stuyver, L.; Chu, C. K.; Schinazi, R. F. Metabolism of the Anti-Hepatitis C Virus Nucleoside β-d-N4-Hydroxycytidine in Different Liver Cells. Antimicrob. Agents Chemother. 2004. https://doi.org/10.1128/AAC.48.12.4636-4642.200 4.
Molnupiravir: coding for catastrophe | Nature Structural & Molecular Biology https://www.nature.com/articles/s41594-021-00657 -8 (accessed 2022 -01 -01).
A High‐Yielding Synthesis of EIDD‐2801 from Uridine** - Steiner - 2020 - European Journal of Organic Chemistry - Wiley Online Library https://chemistry-europe.onlinelibrary.wiley.com/do i/full/10.1002/ejoc.202001340 (accessed 2022 -01 -01).
(24) Vasudevan, N.; Ahlqvist, G. P.; McGeough, C. P.; Paymode, D. J.; Cardoso, F. S. P.; Lucas, T.; Dietz, J.-P.; Opatz, T.; Jamison, T. F.; Gupton, F. B.; Snead, D. R. A Concise Route to MK-4482 (EIDD-2801) from Cytidine. Chem. Commun. Camb. Engl. 2020, 56 (87), 13363–13364. https://doi.org/10.1039/d0cc05944g.
(25) Progress Toward a Large-Scale Synthesis of Molnupiravir (MK-4482, EIDD-2801) from Cytidine | ACS Omega https://pubs.acs.org/doi/10.1021/acsomega.1c00772 ?ref=PDF (accessed 2022 -01 -01).
(26) Gopalsamuthiram, V.; Williams, C.; Noble, J.; Jamison, T. F.; Gupton, B. F.; Snead, D. R. A Concise Route to MK-4482 (EIDD-2801) from Cytidine: Part 2. Synlett 2021, 32 (03), 326–328. https://doi.org/10.1055/a-1275-2848.
(27) Ortiz, C.; Ferreira, M. L.; Barbosa, O.; Santos, J. C. S. dos; Rodrigues, R. C.; Berenguer-Murcia, Á.; Briand, L. E.; Fernandez-Lafuente, R. Novozym 435: The “Perfect” Lipase Immobilized Biocatalyst? Catal. Sci. Technol. 2019, 9 (10), 2380–2420. https://doi.org/10.1039/C9CY00415G.
(28) McIntosh, J. A.; Benkovics, T.; Silverman, S. M.; Huffman, M. A.; Kong, J.; Maligres, P. E.; Itoh, T.; Yang, H.; Verma, D.; Pan, W.; Ho, H.-I.; Vroom, J.; Knight, A. M.; Hurtak, J. A.; Klapars, A.; Fryszkowska, A.; Morris, W. J.; Strotman, N. A.; Murphy, G. S.; Maloney, K. M.; Fier, P. S. Engineered Ribosyl-1-Kinase Enables Concise Synthesis of Molnupiravir, an Antiviral for COVID-19. ACS Cent. Sci. 2021, 7 (12), 1980–1985. https://doi.org/10.1021/acscentsci.1c00608.
Dey, R.; Nayak, S.; Das, P.; Yadav, S. Short Synthesis of Molnupiravir (EIDD-2801) via a Thionated Uridine Intermediate. ACS Omega 2021, 6 (42), 28366–28372. https://doi.org/10.1021/acsomega.1c04550.
Gordon, C. J.; Tchesnokov, E. P.; Schinazi, R. F.; Götte, M. Molnupiravir Promotes SARS-CoV-2 Mutagenesis via the RNA Template. J. Biol. Chem. 2021, 297 (1), 100770. https://doi.org/10.1016/j.jbc.2021.100770.
Tsai, C.-H.; Lee, P.-Y.; Stollar, V.; Li, M.-L. Antiviral Therapy Targeting Viral Polymerase. Curr. Pharm. Des. 2006, 12 (11), 1339–1355. https://doi.org/10.2174/138161206776361156.
Molnupiravir Mutations https://www.science.org/content/blog-post/molnupi ravir-mutations (accessed 2022 -01 -01).
Cox, R. M., Wolf, J. D. & Plemper, R. K. Therapeutically Administered Ribonucleoside Analogue MK-4482/EIDD-2801 Blocks SARS-CoV-2 Transmission in Ferrets. Nat. Microbiol. 6, 11–18 (2021). Https://Www.Fda.Gov/Media/155053/Download
